Sagimet Biosciences (SGMT) Earnings Date & Reports

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SGMT is expected to report earnings to rise 334.62% to -112 cents per share on November 12

Sagimet Biosciences SGMT Stock Earnings Reports

Q3'26

Est.

$-1.13

Q2'26

Beat

by $0.81

Q1'26

Beat

by $0.69

Q4'25

Beat

by $0.91

Q3'25

Beat

by $0.64

The last earnings report on August 11 showed earnings per share of -25 cents, beating the estimate of -107 cents. With 358.84K shares outstanding, the current market capitalization sits at 617.86M.

View a ticker or compare two or three

Ask AI

Compare

Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)

Annualized Return+16%

VIEW DETAILS VIEW DETAILS

VIEW FOR FREE VIEW FOR FREE

SGMT

Setup

Daily Signal:

Description

Gain/Loss: